Logo

Thomas Weisel Partners

Thermo Fisher Strengthens PCR Portfolio with $260M Fermentas Acquisition
Premium

Thomas Weisel Partners called Thermo Fisher's planned $260 million acquisition of Fermentas a "synergistic tuck-in deal" that "bolsters Thermo's capabilities in the high-growth PCR market."

Cepheid Shares Downgraded by Bank

An investment analyst downgraded the shares to "market perform," citing the current hospital spending environment.

Bank Ups 2010 Revenue, EPS Estimates for Waters

The investment bank upped its estimates for the firm, citing a recent meeting with executives who said that they continue to see a stabilization in end markets.

Helicos Cuts Q3 Net Loss by Almost 40 Percent; Rules out Potential Sale of Company

Helicos said that based on its "improving standalone prospects and current market valuation" that it has disengaged from discussions involving a potential sale of the company.

Majority of Proteomic Stimulus Winners Not Likely to Buy Equipment, Analyst Report Finds
Premium

A Thomas Weisel Partners report found that some researchers do not plan to use the stimulus cash to buy equipment, such as mass specs. Rather, a majority said they would use the cash to hire additional personnel.
Breaking News
The Scan

Omicron's Emergence

The World Health Organization has called Omicron a SARS-CoV-2 "variant of concern," the Los Angeles Times writes.

Not as Much

Merck's pill to treat COVID-19 reduces the risk of hospitalization and death among COVID-19 patients by less than previously reported, the New York Times says.

Bats That Hang Together

Discover magazine writes that researchers have found a social microbiome among vampire bats.

PLOS Papers on CEWAS, Simian Varicella Virus Transcriptome, Dermatomyositis Markers

In PLOS this week: multi-omic approach to home in on genetic risk variants, transcriptomic analysis of the simian varicella virus, and more.